 Connection
Arnon Haran to Treatment Outcome
This is a "connection" page, showing publications Arnon Haran has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.079 |
|
|
|
-
Hurvitz N, Amitai I, Yurkovski IL, Tvito A, Ofran Y, Porges T, Wolach O, Sherban A, Even-Zohar NG, Vainstein V, Haran A, Aumann S, Mikhelashvili R, Frisch A, Nachmias B. MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML. Ann Hematol. 2026 May 09; 105(7).
Score: 0.021
-
Gross Even-Zohar N, Aumann S, Shaulov A, Haran A, Nachmias B, Lebel E, Lehmann-Werman R, Gatt ME. First case report of talquetamab use in AL amyloidosis. Leuk Lymphoma. 2025 Dec; 66(14):2618-2623.
Score: 0.020
-
Gross Even Zohar N, Oanunu U, Gross Even-Zohar N, Aumann S, Vainstein V, Gural A, Gatt ME, Haran A, Nachmias B. Prognostic Factors, FLT-3 Mutations, and Treatment Outcomes with Pediatric-Inspired Protocols in Adolescent and Young Adults and Adult Patients with Acute Lymphoblastic Leukemia. Acta Haematol. 2025; 148(6):664-674.
Score: 0.019
-
Frisch A, Ganzel C, Ofran Y, Krayem B, Haran A, Vainstein V, Aumann S, Even-Zohar NG, Nachmias B. Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second Remission. Eur J Haematol. 2025 Apr; 114(4):641-649.
Score: 0.019
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|